Today, Fougera, a division of Nycomed US Inc., announced it has received FDA approval to bring to market the first generic Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution). The generic formulation compares to Dovonex(R) by Warner-Chilcott.
Fougera's Calcipotriene Topical Solution is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp (see product package insert for full prescribing information). It is available in a 60 mL bottle.
"Fougera has received more FDA approvals for topical products during the past seven years than any other generic company. Today's announcement that we are first-to-market with Calcipotriene Topical Solution is another example of our ongoing commitment to provide safe, effective and affordable options to health care providers and their patients," stated David Klaum, Senior Vice President, Commercial Business Operations.
No comments:
Post a Comment